JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M700445200 on February 20, 2007

J. Biol. Chem., Vol. 282, Issue 15, 10981-10987, April 13, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/15/10981    most recent
M700445200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, L.
Right arrow Articles by Cheng, J. Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, L.
Right arrow Articles by Cheng, J. Q.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Akt Attenuation of the Serine Protease Activity of HtrA2/Omi through Phosphorylation of Serine 212*

Lin Yang1, Mei Sun1, Xia-meng Sun, George Z. Cheng, Santo V. Nicosia, and Jin Q. Cheng2

From the Department of Pathology and Cell Biology and Molecular Oncology Program, H. Lee Moffitt Cancer Center and College of Medicine, University of South Florida, Tampa, Florida 33612

Received for publication, January 16, 2007 , and in revised form, February 20, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
The serine protease HtrA2/Omi is released from the mitochondria into the cytosol following apoptosis stimuli, leading to the programmed cell death in caspase-dependent and -independent manners. The function of HtrA2/Omi closely relates to its protease activity, which is required for cleavage of its substrate such as the members of the X-linked inhibitor of apoptotic protein family. However, the regulation of HtrA2/Omi by signaling molecule has not been documented. Here we report that serine/threonine kinases Akt1 and Akt2 phosphorylate mitochondria-released HtrA2/Omi on serine 212 in vivo and in vitro, which results in attenuation of its serine protease activity and pro-apoptotic function. Abolishing HtrA2/Omi phosphorylation by Akt through mutation of serine 212 to alanine (HtrA2/Omi-S212A) retains its serine protease activity and induces more apoptosis as compared with wild-type HtrA2/Omi. Conversely, HtrA2/Omi-S212D, a mutant mimicking phosphorylation, lost the protease activity and failed to induce the programmed cell death. Furthermore, the phosphorylated HtrA2/Omi fails to cleave X-linked inhibitor of apoptotic protein without interfering with their complex formation. In addition, Akt inhibits the release of HtrA2/Omi from the mitochondria into the cytoplasm in response to cisplatin treatment. These data reveal for the first time that HtrA2/Omi is directly regulated by Akt and provide a mechanism by which Akt induces cell survival at post-mitochondrial level.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Akt, also named protein kinase B, represents a family of phosphoinositide 3-kinase-regulated serine/threonine kinases (1–3). Three members of Akt have been identified: Akt1/protein kinase B{alpha}, Akt2/protein kinase Bbeta, and Akt3/protein kinase B{gamma} (4–9), all of which are activated by growth factors in a phosphoinositide 3-kinase-dependent manner (10). Accumulated evidence shows that Akt and its downstream targets constitute a major cell survival pathway. Akt inhibits the programmed cell death in a number of cell types induced by a variety of stimuli through regulation of molecules at both premitochondrial and post-mitochondrial levels (11–13). Several Akt targets have been identified at pre-mitochondrial level. The first Akt target identified was the pro-apoptotic protein BAD (14, 15). BAD is a member of the Bcl-2 family that initiates apoptosis by binding to Bcl-xL and BcL2 on the outer mitochondrial membrane, causing the release of cytochrome c into the cytosol. Akt phosphorylates BAD on serine 136, which promotes the association of BAD with 14-3-3 proteins in the cytosol, thus inactivating its pro-apoptotic function. In addition, Akt reduces the transcription of a subset of pro-apoptotic genes by phosphorylation of Forkhead transcription factors, which causes their nuclear exclusion and inactivation (16). cAMP-response element-binding protein is also phosphorylated and activated by Akt, which leads to an increase in the transcription of anti-apoptotic genes, such as Bcl-2 and Mcl-1 (17–20). In addition, recent studies show Akt direct phosphorylation of BAX and inhibition of BAX activation (21, 22).

A role for an anti-apoptotic function of Akt at a post-mitochondrial level has also been demonstrated (11–13). It has been shown that Akt phosphorylates and inactivates caspase-9 (13). However, the Akt phosphorylation site of caspase-9 (serine 196), present in human, is not conserved in rat and mouse caspase-9 (23). Therefore, the role of caspase-9 in the anti-apoptotic function of Akt remains to be clarified. In response to apoptotic stimuli, the mitochondrial protein HtrA2/Omi is released into the cytoplasm where it binds to and cleaves IAPs3 family proteins resulting in caspase activation (24–27). However, accumulated evidence indicates that HtrA2/Omi also initiates caspase-independent apoptosis in a process that relies entirely on its ability to function as an active protease (24–29).

In the present study, we demonstrated that Akt phosphorylates HtrA2/Omi on serine 212 within serine protease domain in vitro and in vivo and inhibits HtrA2/Omi protease activity. Although the association between HtrA2/Omi and XIAP was not interfered, the ability of HtrA2/Omi to cleave XIAP was attenuated after the phosphorylation by Akt. In addition, Akt also inhibits HtrA2/Omi release from the mitochondria. These data identify HtrA2/Omi as a substrate of Akt and a potentially important mediator of Akt pro-survival function at post-mitochondrial level.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
 REFERENCES
 
Plasmids and Reagents—Hemagglutinin epitope (HA)-tagged wild-type, constitutively active (Myr-Akt), and dominant-negative (kinase-inactive mutant Myr-Akt-K179M) Akt were described previously (30, 31). Myc-tagged wild-type HtrA2/Omi and serine protease dead HtrA2/Omi-S306A were kindly provided by Dr. Ryosuke Takahashi (Brain Science Institute, Wako, Japan) (24). HtrA2/Omi-S212A, HtrA2/Omi-S212D, and HtrA2/Omi-A144G mutant plasmids were created using a QuikChange site-directed mutagenesis kit (Stratagene). A plasmid encoding green fluorescent protein (GFP)-fused HtrA2/Omi was prepared by cloning HtrA2/Omi cDNA into pEGFP-C3 (Clontech) at KpnI/XbaI sites. pLKO.1-Puro-shAKT2 was purchased from Sigma. Antibodies against Akt substrate, XIAP, Akt, poly(ADP-ribose) polymerase, and actin were purchased from Cell Signaling. Anti-HtrA2 antibody was from R&D Systems. Recombinant Akt was obtained from Upstate. Cisplatin and beta-casein were ordered from Sigma.


Figure 1
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 1.
Akt inhibits the apoptosis induced by mature HtrA2/Omi. A, schematic diagram of the domain structure of premature and mature HtrA2/Omi. The premature HtrA2/Omi has an N-terminal putative transmembrane domain (TM) and a serine protease domain adjacent to a PDZ domain at the C terminus. A putative Akt phosphorylation serine residue is located at serine protease domain. B, mature HtrA2/Omi-induced apoptosis is partially reduced by caspase inhibitor and largely inhibited by constitutively active Akt. HeLa cells were transfected with an empty GFP vector or GFP-fused premature or mature HtrA2/Omi together with/without constitutively active Akt. After incubation for 48 h in the absence or presence of caspase inhibitor z-VAD-FMK (ZVAD, 100 µM), the percentages of GFP-positive apoptotic cells were determined by fluorescent microscopy after staining with 4',6-diamidino-2-phenylindole and propidium iodide. C, constitutively active Akt-inhibited apoptosis induced by mature HreA2/Omi is similar to that of protease-inactive mutant M-HtrA2/Omi-S306A. HeLa cells were co-transfected with GFP-M-HtrA2/Omi or GFP-M-HtrA2/Omi-S306A and WT-Akt or constitutively active Akt (myr-Akt). Forty-eight hours after transfection, apoptosis was measured as described in B.

 
Cell Culture and Transfection—Human embryonic kidney (HEK) 293, HeLa, OV2008, A2780S, and OVCAR-3 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Cell transfection was performed with LipofectAMINE Plus (Invitrogen).

Immunoprecipitation, Immunoblotting, and in Vitro Kinase Assay—For immunoprecipitation, cell lysate was incubated with the appropriate antibodies as noted in the figure legends in the presence of protein A-protein G (2:1)-agarose beads. Following wash with lysis buffer, the immunoprecipitates were subjected to Western blotting or in vitro kinase assay analysis. Detection of antigen-bound antibody was carried out with the ECL system (Amersham Biosciences). In vitro protein kinase assay was performed as described previously (32).

In Vivo [32P]Orthophosphate Cell Labeling—HEK293 cells were transfected with pcDNA3-Myc-HtrA2/Omi together with or without wild-type and constitutively active Akt. Following incubation for 36 h, the cells were labeled with [32P]orthophosphate (0.5 mCi/ml) in minimal Eagle's medium without phosphate for 4 h. HtrA2/Omi was immunoprecipitated with anti-Myc antibody. The immunoprecipitates were separated on SDS-PAGE and transferred to membranes. Phosphorylated HtrA2/Omi was detected by autoradiography.

Subcellular Fractionation—Subcellular fractions were prepared by digitonin-based permeabilization buffer as described (33). The relative purity of the subcellular fractions was confirmed by Western blot using anti-actin (cytosolic marker) and anti-Cox-4 (mitochondrial marker) antibodies.

Apoptosis Assay—Cells were transfected with GFP-fused mature HtrA2/Omi, HtrA2/Omi-S212A, or HtrA2/Omi-S212D and GFP alone as a control. After 48 h of transfection, the cells were stained with 4',6-diamidino-2-phenylindole, and apoptosis was examined using fluorescence microscopy in GFP-expressing cells. The percentage of apoptotic cell was expressed as the mean number of apoptotic cells in a fraction of the total number of GFP-expressing cells. For ovarian cancer cells, the cells were infected with shRNA of Akt (Sigma) and then treated with cisplatin and Akt/PKB inhibitor-2, API-2. Apoptotic cells were detected with TUNEL assay (12).

In Vitro Proteolytic Cleavage Assay for HtrA2/Omi—Mature GST-HtrA2/Omi, -HtrA2/Omi-S212A, -HtrA2/Omi-S212D, and -HtrA2/Omi-S306A fusion proteins were expressed and purified as described previously (24). Their proteolytic activity was detected by incubation of the fusion proteins with 1.2 µg of beta-casein (Sigma) or XIAP recombinant protein for 1 h at 37°C in 50 mM Tris-HCl (pH 8.0). Where indicated, some GST-HtrA2/Omi fusion proteins were incubated with an excess of recombinant Akt protein (Upstate%20Biotechnology">Upstate Biotechnology) for 30 min at 25 °C prior to the addition of beta-casein or XIAP. The reactions were separated on SDS-PAGE and stained with Coomassie Blue.


Figure 2
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 2.
Serine protease activity of HtrA2/Omi is inhibited by Akt. In vitro protease assay was performed by incubation of recombinant mature HtrA2/Omi with beta-casein (A) or GST-XIAP (B) in the presence or the absence of recombinant constitutively active Akt. Two hours after the incubation, the reactions were separated in a SDS-PAGE and visualized (upper panel). The middle and bottom panels show HtrA2/Omi and Akt proteins used in the assay.

 


Figure 3
View larger version (51K):
[in this window]
[in a new window]

  		FIGURE 3.
Serine-212 of HtrA2/Omi is phosphorylated by Akt1 and Akt2 in vivo and in vitro. A, comparison of putative Akt phosphorylation site in HtrA2/Omi with the sequences of phosphorylation sites of known Akt substrates. The phosphorylated residues are labeled by number, and a consensus sequence is denoted below. B, Akt phosphorylation of HtrA2/Omi in vivo. HEK293 cells were transfected with indicated plasmids and labeled with [32P]orthophosphate. Myc-tagged mature HtrA2/Omi was immunoprecipitated with anti-Myc antibody and separated by SDS-PAGE, transferred to a membrane, exposed to a film (top panel), and subsequently detected with anti-HtrA2/Omi antibody (panel 2). Expression of HA-myr-Akt1 or HA-myr-Akt2 is shown in the bottom panel. C, serine 212 of HtrA2/Omi is phosphorylated by Akt in vitro. In vitro kinase assay was performed by incubation of the immunoprecipitated HA-Myr-Akt1 or -Akt2 with GST-HtrA2/Omi or GST-HtrA2/Omi-S212A as substrate (top panel). The bottom panel shows expression of transfected Akt1 or Akt2. D, Akt phosphorylates serine 212 of HtrA2/Omi in vivo. HEK293 cells were transfected with indicated plasmids. Following incubation for 36 h, cells were lysed and immunoblotted with the antibodies against Akt substrates (Cell Signaling, upper panel), Myc (panel 2), HA (panel 3), and actin (bottom panel). E, Akt phosphorylates endogenous cytoplasmic HtrA2/Omi and inhibits its release from mitochondria. OV2008 ovarian cancer cells, which express high level of Akt1, were treated with cisplatin, API-2, and/or Akt-shRNA, fractionated, and then immunoprecipitated with anti-HtrA2/Omi antibody (R&D Systems). The HtrA2/Omi immunoprecipitates were immunoblotted with anti-Akt substrate antibody (panels 1 and 6). Total HtrA2/Omi and Akt as well as phospho-Akt in cytoplasmic and mitochondrial fractions were analyzed by Western blot with indicated antibodies (panels 2–4, 7, and 8). We noted that the mitochondrial (premature) HtrA2/Omi is ~15-kDa larger than cytoplasmic (mature) HtrA2/Omi. Panels 5 and 9 show relatively equal loading.

 

   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
REFERENCES
 
Akt Inhibits the Apoptosis Induced by Mature HtrA2/Omi—The serine protease HtrA2/Omi is synthesized as a precursor (premature HtrA2/Omi) that normally localizes at the mitochondria in healthy cell. Following apoptotic stimuli, the N-terminal amino acids preceding alanine 134 are cleaved and the resulted mature HtrA2/Omi is released from the mitochondria into the cytoplasm where it induces apoptosis (24–29). It has been shown that mature HtrA2/Omi functions as an antagonizer of members of IAP family proteins that normally bind to and inhibit caspase-3, -7, and -9 (24–27). However, accumulated studies indicate that serine protease activity of HtrA2/Omi plays a more critical role than its antagonizing IAPs in inducing apoptosis (27–29), whereas the cleaving targets remain to be fully characterized (25, 26). Mutation of serine 306 to alanine within protease domain abrogates its serine protease and pro-apoptotic activity. Thus, HtrA2/Omi pro-apoptotic function is mediated through caspase-dependent and -independent mechanisms and totally relies on its serine protease activity (24–29, 34–36). Because Akt exerts anti-apoptotic function at both pre- and post-mitochondrial levels, its one or more targets at post-mitochondrial level remain elusive, and the serine protease domain of HtrA2/Omi contains an Akt phosphorylation consensus site (Fig. 1A), we examined if HtrA2/Omi pro-apoptotic function is regulated by Akt. HeLa cells were transfected with GFP-fused premature or mature HtrA2/Omi (Fig. 1A) together with or without wild-type and constitutively active Akt and then treated with or without pan-caspase inhibitor z-VAD-FMK. Apoptotic cells were examined and accounted under fluorescent microscopy after staining with 4',6-diamidino-2-phenylindole and propidium iodide. As expected, ectopic expression of premature HtrA2/Omi did not increase apoptosis as compared with GFP vector control, whereas expression of mature HtrA2/Omi considerably induced the programmed cell death (Fig. 1, B and C). The apoptosis induced by mature HtrA2/Omi was largely reduced by expression of Akt, especially constitutively active Akt. The magnitude of constitutively active Akt-inhibited cell death is similar to that of protease-inactive mutant HtrA2/Omi-S306A (Fig. 1C). However, the z-VAD-FMK only reduces the mature HtrA2/Omi-induced cell death by ~45% (Fig. 1B). These findings indicate that Akt inhibits HtrA2/Omi pro-apoptotic function and further support the notion that HtrA2/Omi induces apoptosis through caspase-dependent and -independent pathways.


Figure 4
View larger version (46K):
[in this window]
[in a new window]

  		FIGURE 4.
Phosphorylation of serine 212 of HtrA2/Omi by Akt abrogates its protease activity and overrides the HtrA2/Omi down-regulation of XIAP. A, Akt inhibition of HtrA2/Omi serine protease activity depends on phosphorylation of serine 212. In vitro protease assay was performed as described in Fig. 2. Different forms of mature HtrA2/Omi were incubated with beta-casein (upper panel) or GST-XIAP (panel 2) in the presence or the absence of recombinant constitutively active Akt. Equal amounts of M-HtrA2/Omi and Akt proteins used in the assay are shown in panels 3 and 4. B, Akt inhibition of HtrA2/Omi down-regulation of XIAP depends on the phosphorylation of serine 212. HeLa cells were transfected with indicated plasmids, and endogenous XIAP was analyzed by Western blot with anti-XIAP antibody (upper panel). Expression of transfected different forms of HtrA2/Omi and Akt is shown in the panels 2 and 3. The blot was reprobed with anti-actin antibody (bottom panel). C and D, Akt phosphorylation of HtrA2/Omi does not interfere with the interaction between HtrA2/Omi and XIAP. HEK293 cells were co-transfected with the indicated plasmids. After incubation for 36 h, cells were lysed, immunoprecipitated, and detected with indicated antibodies (top panels of C and D). The middle and bottom panels show expression of transfected plasmids.

 
HtrA2/Omi Serine Protease Activity Is Attenuated by Akt—Because serine protease activity of HtrA2/Omi is required for its pro-apoptotic function (27–29, 34–36), we next examined if Akt inhibits the serine protease activity of HtrA2/Omi. In vitro protease assay was performed by incubation of recombinant mature HtrA2/Omi and beta-casein, as substrate, together with or without constitutively active or dominant negative Akt. In the absence of Akt, the beta-casein was largely cleaved by HtrA2/Omi. However, the cleavage was greatly reduced by preincubation of the HtrA2/Omi with constitutively active Akt but not dominant negative Akt (Fig. 2A). Because XIAP is a physiological substrate of HtrA2/Omi (34, 35), we further examined if Akt inhibits HtrA2/Omi cleavage of XIAP. GST-fused XIAP was incubated with mature HtrA2/Omi together with or without constitutively active and dominant negative Akt. Similarly, mature HtrA2/Omi effectively cleaved XIAP, and the cleavage was attenuated by constitutively active Akt but not dominant negative Akt (Fig. 2B). These results indicate that the serine protease activity of HtrA2/Omi is abrogated by Akt through a kinase-dependent manner.

HtrA2/Omi Is Phosphorylated by Akt in Vitro and in Vivo—To define the underlying mechanism of Akt inhibition of serine protease activity of HtrA2/Omi, we performed co-immunoprecipitation assay and observed no interaction between HtrA2/Omi and Akt (data not shown). Because HtrA2/Omi contains an Akt phosphorylation consensus site within its protease domain (Fig. 1A), which is conserved between human, rat, and mouse (Fig. 3A), we next investigated if Akt phosphorylates HtrA2/Omi. An in vivo [32P]orthophosphate cell-labeling experiment was performed in HEK293 cells. Fig. 3B shows that basal phosphorylation level of mature HtrA2/Omi is low. Expression of constitutively active Akt1 and Akt2 considerably induced HtrA2/Omi phosphorylation. To define Akt phosphorylation site of HtrA2/Omi, in vitro kinase assay was carried out using GST-fused wild-type HtrA2/Omi and mutant HtrA2/Omi-S212A as substrates. Repeated experiments revealed that both constitutively active Akt1 and Akt2 highly phosphorylate the wild-type GST-HtrA2/Omi but not HtrA2/Omi-S212A (Fig. 3C), indicating Akt phosphorylation of HtrA2/Omi on serine 212 in vitro.

We next examined if Akt phosphorylates serine 212 of HtrA2/Omi in vivo. HEK293 cells were transfected with wild-type and S212A-mutant HtrA2/Omi together with or without constitutively active Akt1 and Akt2. Immunoblotting analysis with the antibody that specifically recognizes Akt substrate revealed that wild-type HtrA2/Omi, but not HtrA2/Omi-S212A, was phosphorylated by Akt (Fig. 3D). These data indicate that Akt phosphorylates serine 212 of HtrA2/Omi in vitro and in vivo.

Akt Phosphorylates Endogenous Cytoplasmic HtrA2/Omi—To demonstrate if phosphorylation of HtrA2/Omi by Akt occurs at endogenous protein level and if Akt is a bona fide kinase for HtrA2/Omi, we knocked down Akt by infection of OV2008 ovarian cancer cells with lentiviruses expressing shRNA of Akt1. Following incubation for 72 h, the cells were treated with or without cisplatin and Akt inhibitor API-2 (37) and then fractionated. Total and phosphorylated HtrA2/Omi and Akt were examined in the cytoplasmic and mitochondrial fractions. Immunoblotting analysis of HtrA2/Omi immunoprecipitates with anti-Akt substrate antibody revealed that the cytoplasmic but not mitochondrial HtrA2/Omi was phosphorylated by Akt. The knockdown of Akt or the inhibition of Akt kinase with API-2 largely reduced the phosphorylation level of HtrA2/Omi (Fig. 3E). As expected, HtrA2/Omi was released from the mitochondria into the cytoplasm in response to cisplatin treatment in OV2008 cells. Moreover, cytoplasmic level of HtrA2/Omi was further increased by knockdown of Akt or treatment with Akt inhibitor API-2 (Fig. 3E), suggesting that Akt not only phosphorylates endogenous HtrA2/Omi in the cytoplasm but also inhibits its release from the mitochondria.


Figure 5
View larger version (51K):
[in this window]
[in a new window]

  		FIGURE 5.
Akt inhibition of HtrA2/Omi pro-apoptotic function depends on the phosphorylation of serine 212. A and B, Akt inhibits poly(ADP-ribose) polymerase (PARP) cleavage induced by mature HtrA2/Omi but not by non-phosphorylatable HtrA2/Omi-S212A. HeLa cells were transfected with M-HtrA2/Omi (A) or M-HtrA2/Omi-S212A (B) and constitutively active Akt. After 48 h of transfection, poly(ADP-ribose) polymerase cleavage was detected by Western blot (upper panel). Expression of transfected HtrA2/Omi and Akt was detected with anti-Myc (panel 2) and anti-HA (panel 3) antibodies. The blot was rehybridized with anti-actin antibody (bottom panel). C and D, constitutively active Akt inhibits wild-type but not non-phosphorylatable HtrA2/Omi-induced apoptosis. HeLa cells were transfected with the indicated plasmids. Apoptosis was examined with a TUNEL assay (C). D, quantification of apoptotic cell from three experiments in triplicate.

 
Akt Inhibits HtrA2/Omi Serine Protease Activity through a Phosphorylation-dependent Manner—Because Akt phosphorylates HtrA2/Omi and inhibits its serine protease activity, we next asked if the phosphorylation of serine 212 is required for inhibition of HtrA2/Omi protease activity. In vitro protease assay was performed by incubation of different forms of HtrA2/Omi with beta-casein or recombinant XIAP in the presence or the absence of Akt. Fig. 4A shows that beta-casein and XIAP were largely cleaved by HtrA2/Omi-S212A, a mutant that could not be phosphorylated by Akt. Unlike wild-type HtrA2/Omi whose activity was inhibited by Akt (Fig. 2), the ability of HtrA2/Omi-S212A to cleave beta-casein and XIAP was not affected by Akt. In contrast, HtrA2/Omi-S212D, a mutant mimicking phosphorylation, failed to cleave beta-casein and XIAP, suggesting that inhibition of HtrA2/Omi protease activity by Akt depends on the phosphorylation of serine 212. A recent study showed that HtrA2/Omi forms the homotrimeric structure that is indispensable for executing its serine protease activity (38). Thus, Akt phosphorylation of serine 212 within the serine protease domain of HtrA2/Omi (Fig. 1A) might interfere with the homotrimeric formation. However, the detailed mechanism needs to be further investigated.

Further, we investigated the effects of Akt phosphorylation of HtrA2/Omi on XIAP expression in living cells. HeLa cells were transfected with different forms of HtrA2/Omi together with or without constitutively active Akt. Immunoblotting analysis revealed that the protein level of XIAP was considerably reduced in the cells expressing mature HtrA2/Omi and non-phosphorylatable HtrA2/Omi-S212A, whereas phosphomimic HtrA2/Omi-S212D had no effect on XIAP expression. Furthermore, expression of constitutively active Akt overrode the inhibitory effects of wild-type but not non-phosphorylatable HtrA2/Omi on XIAP expression (Fig. 4B).

Previous studies have demonstrated that the cleavage of XIAP by HtrA2/Omi is also dependent on the interaction between HtrA2/Omi and XIAP (27–29, 32, 35). Therefore, we further examined if Akt phosphorylation of HtrA2/Omi interferes with HtrA2/Omi-XIAP complex formation. A co-immunoprecipitation experiment showed that phosphomimic and non-phosphorylatable HtrA2/Omi had similar capability of binding to XIAP. Expression of constitutively active Akt had no effect on the interaction (Fig. 4, C and D), indicating that the phosphorylation of serine 212 of HtrA2/Omi does not interfere with its N-terminal conserved IAP-binding motif, 134AVPS137 (Fig. 1A) (25). As a control, we also created HtrA2/Omi-A144G mutant by converting alanine 144 glycine. Consistent with previous finding (27), HtrA2/Omi-A144G failed to bind to XIAP (Fig. 4C). Taken collectively, these data indicate that Akt phosphorylation of HtrA2/Omi at serine 212 is a critical event for attenuation of HtrA2/Omi cleaving XIAP, although it does not affect HtrA2/Omi-XIAP complex formation.

Akt Abrogates HtrA2/Omi Pro-apoptotic Function through Phosphorylation of HtrA2/Omi and Inhibition of Its Release from Mitochondria—Because mature HtrA2/Omi plays an important role in inducing the programmed cell death at post-mitochondrial level (27–29, 34–36), and Fig. 3E shows Akt inhibition of HtrA2/Omi release from the mitochondria, we next examined whether Akt anti-apoptotic function is mediated by phosphorylation of HtrA2/Omi and inhibition of its release from mitochondria. HeLa cells were transfected with different forms of mature HtrA2/Omi together with or without constitutively active and dominant negative Akt. As a control, the cells were also transfected with pcDNA vector alone. Immunoblotting and TUNEL assays revealed that ectopic expression of wild-type HtrA2/Omi and non-phosphorylatable HtrA2/Omi-S212A-induced poly(ADP-ribose) polymerase cleavage (Fig. 5, A and B, and data not shown) and programmed cell death (Fig. 5, C and D). Constitutively active Akt inhibits wild-type HtrA2/Omi- but not HtrA2/Omi-S212A-induced apoptosis, whereas dominant negative Akt moderately increased the apoptosis induced by mature HtrA2/Omi (Fig. 5, A–D). Moreover, phosphomimic HtrA2/Omi-S212D failed to provoke the programmed cell death (Fig. 5, C and D).


Figure 6
View larger version (36K):
[in this window]
[in a new window]

  		FIGURE 6.
Regulation of endogenous HtrA2/Omi by Akt. A, knockdown of AKT2. OVCAR3 cells, which overexpress AKT2, were infected with lentiviruses expressing shRNA-AKT2 or control shRNA. After selection with puromycin, pooled cells were lysed and immunoblotted with anti-AKT2 (top) and -actin (bottom) antibodies. B, knockdown of AKT2 in OVCAR3 cells increases cisplatin-induced HtrA2/Omi release but decreases the phosphorylation level of HtrA2/Omi. Cells were treated with cisplatin (20µM) for indicated times, lysed, fractionated, immunoprecipitated and/or immunoblotted with the indicated antibodies as described in Fig. 3D (panels 1–5). The bottom panel represents the result from TUNEL assay. Each experiment was performed three times in triplicate. C, expression of Akt inhibits HtrA2/Omi release. A2780S cells were transfected with constitutively active Akt or pcDNA vector alone. After treatment with cisplatin for 18 h, cytoplasmic levels of HtrA2/Omi were examined with Western blot analysis (top). The blot was rehybridized with anti-HA (middle) and -actin (bottom) antibodies. D, schematic illustration of Akt regulation of HtrA2/Omi.

 
To examine if Akt promotes cell survival by phosphorylation of endogenous HtrA2/Omi and inhibition of its release from the mitochondria, OVCAR-3 ovarian cancer cells, which overexpress AKT2 (7), were infected with shAKT2-lentiviruse (pLKO.1-Puro-shAKT2) and pLKO.1-Puro control shRNA (Fig. 6A). Following selection with puromycin for 2 weeks, the pooled cells were treated with cisplatin for different time points. Consistent with the findings of Akt1 knockdown in OV2008 cells (Fig. 3E), knockdown of AKT2 considerably enhanced HtrA2/Omi release from the mitochondria into the cytoplasm following cisplatin treatment. However, the phosphorylation level of HtrA2/Omi was reduced by knockdown of AKT2 as compared with the cells infected with control shRNA. Accordingly, cisplatin-induced apoptosis was increased in AKT2-knockdown cells (Fig. 6B). To further demonstrate the effect of Akt on HtrA2/Omi release from the mitochondria in response to apoptotic stimulation, A2780S cells, which express low level of Akt and are sensitive to cisplatin, were transfected with constitutively active Akt or pcDNA3 and then treated with or without cisplatin. Immunoblotting analysis of cytoplasmic fraction revealed that expression of constitutively active Akt reduced HtrA2/Omi release from the mitochondria into the cytosol more than 1 fold (Fig. 6C), which is consistent with a recent report (40) showing inhibition of HtrA2/Omi release by expression of constitutively active Akt2 in A2780S cells. Taken collectively, we conclude that Akt abrogates HtrA2/Omi pro-apoptotic function through phosphorylation of serine 212 in cytoplasm and inhibition of its release from the mitochondria (Fig. 6D).

HtrA2/Omi as an apoptosis inducer has recently been challenged by a recent study that used HtrA2/Omi knock-out or mutant mice. HtrA2/Omi knock-out mice showed no reduced rate of cell death but suffered loss of a population of neurons in the striatum (41). Furthermore, a mutation in the protease domain of HtrA2/Omi has been identified as a cause of lethal neuromuscular wasting disorder in mnd2 (motor neuromuscular degeneration 2) mice (42). However, a number of reports have shown that, following apoptotic stimuli, premature HtrA2/Omi is cleaved, and the resulted mature HtrA2/Omi is released from the mitochondria into the cytosol where it mediates the programmed cell death through a serine protease-dependent mechanism (24–29, 39, 43–50). Based on those findings, HtrA2/Omi could act on maintenance of mitochondrial homeostasis in normal cells and mitochondrial HtrA2/Omi could have different function from the one in the cytoplasm. In fact, premature HtrA2/Omi locates at the mitochondria in healthy cells, whereas apoptotic stimuli-induced mature HtrA2/Omi, which is 134 amino acids shorter than its premature form, is detected in the cytosol. The data from others and ours also show that expression of mature but not premature HtrA2/Omi provokes the programmed cell death (Fig. 1). Nevertheless, the data presented in this study demonstrate for the first time that HtrA2/Omi is regulated by phosphorylation. Akt phosphorylates HtrA2/Omi on serine 212 in vitro and in vivo. The phosphorylation of HtrA2/Omi by Akt results in abrogation of its serine protease and pro-apoptotic activities. Future investigations are required for determining the in vivo effect of Akt phosphorylation of HtrA2/Omi using an HtrA2/Omi-S212D or/and -S212A knock-in mouse model.


   FOOTNOTES
 
* This work was supported by grants from the National Institutes of Health and Department of Defense (to J. Q. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Both authors contributed equally to this work. Back

2 To whom correspondence should be addressed: H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Tel.: 813-745-6915; Fax: 813-745-3928; E-mail: jin.cheng{at}moffitt.org.

3 The abbreviations used are: IAP, inhibitor of apoptotic protein; XIAP, X-linked IAP; HA, hemagglutinin; GFP, green fluorescence protein; HEK, human embryonic kidney cells; shRNA, short hairpin RNA; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling; GST, glutathione S-transferase; z, benzyloxycarbonyl; FMK, fluoromethyl ketone. Back


   ACKNOWLEDGMENTS
 
We are grateful to the DNA Sequence and Flow Cytometry Facilities at the H. Lee Moffitt Cancer Center.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. (1995) Cell 81, 727–736[CrossRef][Medline] [Order article via Infotrieve]
  2. Burgering, B. M., and Coffer, P. J. (1995) Nature 376, 599–602[CrossRef][Medline] [Order article via Infotrieve]
  3. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785–789[CrossRef][Medline] [Order article via Infotrieve]
  4. Bellacosa, A., Testa, J. R., Staal, S. P., and Tsichlis, P. N. (1991) Science 254, 274–277[Abstract/Free Full Text]
  5. Jones, P. F., Jakubowicz, T., Pitossi, F. J., Maurer, F., and Hemmings, B. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4171–4175[Abstract/Free Full Text]
  6. Coffer, P. J., and Woodgett, J. R. (1991) Eur. J. Biochem. 201, 475–481[Medline] [Order article via Infotrieve]
  7. Cheng, J. Q., Godwin, A. K., Belacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., and Testa, J. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9267–9271[Abstract/Free Full Text]
  8. Jones, P. F., Jakubowicz, T., and Hemmings, B. A. (1991) Cell Regul. 2, 1001–1009[Medline] [Order article via Infotrieve]
  9. Nakatani, K., Sakaue, H., Thompson, D. A., Weigel, R. J., and Roth, R. A. (1999) Biochem. Biophys. Res. Commun. 257, 906–910[CrossRef][Medline] [Order article via Infotrieve]
  10. Datta, S. R., Brunet, A., and Greenberg, M. E. (1999) Genes Dev. 13, 2905–2927[Free Full Text]
  11. Zhou, H., Li, X. M., Meinkoth, J., and Pittman, R. N. (2000) J. Cell Biol. 151, 483–494[Abstract/Free Full Text]
  12. Dan, H. C., Sun, M., Kaneko, S., Feldman, R. I., Nicosia, S. V., Wang, H. G., Tsang, B. K., and Cheng, J. Q. (2004) J. Biol. Chem. 279, 5405–5412[Abstract/Free Full Text]
  13. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Science 282, 1318–1321[Abstract/Free Full Text]
  14. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231–241[CrossRef][Medline] [Order article via Infotrieve]
  15. del Peso, L., Gonzalez-Garcia, M., Page, Herrera, C. R., and Nunez, G. (1997) Science 278, 687–689[Abstract/Free Full Text]
  16. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96, 857–868[CrossRef][Medline] [Order article via Infotrieve]
  17. Du, K., and Montminy, M. (1998) J. Biol. Chem. 273, 32377–32379[Abstract/Free Full Text]
  18. Pugazhenthi, S., Nesterova, A., Sable, C., Heidenreich, K. A., Boxer, L. M., Heasley, L. E., and Reusch, J. E. (2000) J. Biol. Chem. 275, 10761–10766[Abstract/Free Full Text]
  19. Riccio, A., Ahn, S., Davenport, C. M., Blendy, J. A., and Ginty, D. D. (1999) Science 286, 2358–2361[Abstract/Free Full Text]
  20. Wang, J. M., Chao, J. R., Chen, W., Kuo, M. L., Yen, J. J., and Yang-Yen, H. F. (1999) Mol. Cell Biol. 19, 6195–6206[Abstract/Free Full Text]
  21. Gardai, S. J., Hildeman, D. A., Frankel, S. K., Whitlock, B. B., Frasch, S. C., Borregaard, N., Marrack, P., Bratton, D. L., and Henson, P. M. (2004) J. Biol. Chem. 279, 21085–21095[Abstract/Free Full Text]
  22. Xin, M., and Deng, X. (2005) J. Biol. Chem. 280, 10781–10789[Abstract/Free Full Text]
  23. Fujita, E., Jinbo, A., Matuzaki, H., Konishi, H., Kikkawa, U., and Momoi, T. (1999) Biochem. Biophys. Res. Commun. 264, 550–555[CrossRef][Medline] [Order article via Infotrieve]
  24. Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., and Takahashi, R. (2001) Mol. Cell 8, 613–621[CrossRef][Medline] [Order article via Infotrieve]
  25. Hegde, R., Srinivasula, S. M., Zhang, Z., Wassell, R., Mukattash, R., Cilenti, L., DuBois, G., Lazebnik, Y., Zervos, A. S., Fernandes-Alnemri, T., and Alnemri, E. S. (2002) J. Biol. Chem. 277, 432–438[Abstract/Free Full Text]
  26. Martins, L. M., Iaccarino, I., Tenev, T., Gschmeissner, S., Totty, N. F., Lemoine, N. R., Savopoulos, J., Gray, C. W., Creasy, C. L., Dingwall, C., and Downward, J. (2002) J. Biol. Chem. 277, 439–444[Abstract/Free Full Text]
  27. Verhagen, A. M., Silke, J., Ekert, P. G., Pakusch, M., Kaufmann, H., Connolly, L. M., Day, C. L., Tikoo, A., Burke, R., Wrobel, C., Moritz, R. L., Simpson, R. J., and Vaux, D. L. (2002) J. Biol. Chem. 277, 445–454[Abstract/Free Full Text]
  28. Blink, E., Maianski, N. A., Alnemri, E. S., Zervos, A. S., Roos, D., and Kuijpers, T. W. (2004) Cell Death Differ. 11, 937–939[CrossRef][Medline] [Order article via Infotrieve]
  29. Suzuki, Y., Takahashi-Niki, K., Akagi, T., Hashikawa, T., and Takahashi, R. (2004) Cell Death Differ. 11, 208–216[CrossRef][Medline] [Order article via Infotrieve]
  30. Ahmed, N. N., Franke, T. F., Bellacosa, A., Datta, K., Gonzalez-Portal, M. E., Taguchi, T., Testa, J. R., and Tsichlis, P. N. (1993) Oncogene 8, 1957–1963[Medline] [Order article via Infotrieve]
  31. Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z. Q., Ma, X. L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., and Cheng, J. Q. (2001) Am. J. Pathol. 159, 431–437[Abstract/Free Full Text]
  32. Liu, A.-X., Testa, J. R., Hamilton, T. C., Jove, R., Nicosia, S. V., and Cheng, J. Q. (1998) Cancer Res. 58, 2973–2977[Abstract/Free Full Text]
  33. Gao, M., Fan, S., Goldberg, I. D., Laterra, J., Kitsis, R. N., and Rosen, E. M. (2001) J. Biol. Chem. 276, 47257–47265[Abstract/Free Full Text]
  34. Srinivasula, S. M., Gupta, S., Datta, P., Zhang, Z., Hegde, R., Cheong, N., Fernandes-Alnemri, T., and Alnemri, E. S. (2003) J. Biol. Chem. 278, 31469–31472[Abstract/Free Full Text]
  35. Seong, Y. M., Choi, J. Y., Park, H. J., Kim, K. J., Ahn, S. G., Seong, G. H., Kim, I. K., Kang, S., and Rhim, H. (2004) J. Biol. Chem. 279, 37588–37596[Abstract/Free Full Text]
  36. Cilenti, L., Kyriazis, G. A., Soundarapandian, M. M., Stratico, V., Yerkes, A., Park, K. M., Sheridan, A. M., Alnemri, E. S., Bonventre, J. V., and Zervos, A. S. (2005) Am. J. Physiol. 288, F371–F379
  37. Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., Sebti, S. M., and Cheng, J. Q. (2004) Cancer Res. 64, 4394–4399[Abstract/Free Full Text]
  38. Nam, M. K., Seong, Y. M., Park, H. J., Choi, J. Y., Kang, S., and Rhim, H. (2006) Exp. Mol. Med. 38, 36–43[Medline] [Order article via Infotrieve]
  39. Ekert, P. G., and Vaux, D. L. (2005) Curr. Opin. Cell Biol. 17, 626–630[CrossRef][Medline] [Order article via Infotrieve]
  40. Yang, X., Fraser, M., Moll, U. M., Basak, A., and Tsang, B. K. (2006) Cancer Res. 66, 3126–3136[Abstract/Free Full Text]
  41. Martins, L. M., Morrison, A., Klupsch, K., Fedele, V., Moisoi, N., Teismann, P. Abuin, A., Grau, E., Geppert, M., Livi, G. P., Creasy, C. L., Martin, A., Hargreaves, I., Heales, S. J., Okada, H., Brandner, S., Schulz, J. B., Mak, T., and Downward, J. (2004) Mol. Cell Biol. 24, 9848–9862[Abstract/Free Full Text]
  42. Jones, J. M., Datta, P., Srinivasula, S. M., Ji, W., Gupta, S., Zhang, Z., Davies, E., Hajnoczky, G., Saunders, T. L., Van Keuren, M. L., Fernandes-Alnemri, T., Meisler, M. H., and Alnemri, E. S. (2003) Nature 425, 721–727[CrossRef][Medline] [Order article via Infotrieve]
  43. Liu, Z., Li, H., Derouet, M., Berezkin, A., Sasazuki, T., Shirasawa, S., and Rosen, K. (2006) J. Biol. Chem. 281, 14738–14747[Abstract/Free Full Text]
  44. Munoz-Pinedo, C., Guio-Carrion, A., Goldstein, J. C., Fitzgerald, P., Newmeyer, D. D., and Green, D. R. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 11573–11578[Abstract/Free Full Text]
  45. Kuninaka, S., Nomura, M., Hirota, T., Iida, S., Hara, T., Honda, S., Kunitoku, N., Sasayama, T., Arima, Y., Marumoto, T., Koja, K., Yonehara, S., and Saya, H. (2005) Oncogene 24, 5287–5298[CrossRef][Medline] [Order article via Infotrieve]
  46. Liu, H. R., Gao, E., Hu, A., Tao, L., Qu, Y., Most, P., Koch, W. J., Christopher, T. A., Lopez, B. L., Alnemri, E. S., Zervos, A. S., and Ma, X. L. (2005) Circulation 111, 90–96
  47. Althaus, J., Siegelin, M. D., Dehghani, F., Cilenti, L., Zervos, A. S., and Rami, A. (2007) Neurochem. Int. 50, 172–180[CrossRef][Medline] [Order article via Infotrieve]
  48. Trencia, A., Fiory, F., Maitan, M. A., Vito, P., Barbagallo, A. P., Perfetti, A., Miele, C., Ungaro, P., Oriente, F., Cilenti, L., Zervos, A. S., Formisano, P., and Beguinot, F. (2004) J. Biol. Chem. 279, 46566–46572[Abstract/Free Full Text]
  49. Gamero, A. M., Potla, R., Sakamoto, S., Baker, D. P., Abraham, R., and Larner, A. C. (2006) Cell Signal. 18, 1299–1308[CrossRef][Medline] [Order article via Infotrieve]
  50. Bhuiyan, M. S., and Fukunaga, K. (2006) Eur. J. Pharmacol. 557, 168–177

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Plun-Favreau and J. Hardy
PINK1 in mitochondrial function
PNAS, August 12, 2008; 105(32): 11041 - 11042.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Monick, L. S. Powers, C. W. Barrett, S. Hinde, A. Ashare, D. J. Groskreutz, T. Nyunoya, M. Coleman, D. R. Spitz, and G. W. Hunninghake
Constitutive ERK MAPK Activity Regulates Macrophage ATP Production and Mitochondrial Integrity
J. Immunol., June 1, 2008; 180(11): 7485 - 7496.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. J. Huttunen, S. Y. Guenette, C. Peach, C. Greco, W. Xia, D. Y. Kim, C. Barren, R. E. Tanzi, and D. M. Kovacs
HtrA2 Regulates beta-Amyloid Precursor Protein (APP) Metabolism through Endoplasmic Reticulum-associated Degradation
J. Biol. Chem., September 21, 2007; 282(38): 28285 - 28295.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/15/10981    most recent
M700445200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, L.
Right arrow Articles by Cheng, J. Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, L.
Right arrow Articles by Cheng, J. Q.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.